Please select a video from the list below.
SIOVAC: Sildenafil for PH after Mitral Valve Surgery
PH in valvular heart disease remains an enigmatic disease with up to 75% of patients experiencing residual or persistent PH after valvular correction. Dr. Vallerie McLaughlin reviews the recent SIOVAC trial, which examined the efficacy and safety of sildenafil in patients with corrected valvular heart disease and persistent PH. Important efficacy and safety information is brought to light that may impact how physicians approach treatment in this difficult-to-treat population.
Recent Video
Most Viewed
Specialties :                    Search :
RESPITE Study Results
RESPITE Study Results Views - 1049
ICU Management of PH
ICU Management of PH Views - 151